The BIA campaigns for finance, tax and investment policies to support UK bioscience companies to start and scale-up.
The Finance and Tax Advisory Committee (FTAC) leads the BIA’s policy development, drawing on the expertise and experience of the membership. Our strong links to the Treasury, HMRC and the Department for Business, Energy and Industrial Strategy ensure that the voice of the bioscience sector is heard at the highest levels.
FTAC also provides finance and tax support for BIA members through events and guidance documents.
The BIA works with the investment community to raise to profile of UK bioscience and publishes quartlery reports on the levels of investment in the sector. The UK is the European leader in bioscience investment and is in a strong position to close the gap on the leading life sciences clusters in Boston and San Francisco and achieve the BIA's vision of becoming the world's third largest global biotech cluster. Check out the image gallery below for more on our 2018 finance report, Confident capital: backing UK biotech.
1 of 4
A total of £958m was raised through IPOs by Europe-based biotech companies in 2018. The UK was the stand-out performer, accounting for a third of IPOs and 45% of capital raised.
2 of 4
UK biotech financing accelerated in 2018, far exceeding any previous year since the BIA began publishing these reports in 2013. A total of £2.2bn was raised by UK-based biotech companies during the period covered by this report, £1bn more than the previous year.
3 of 4
UK venture capital funding over the last five years
IInvestor appetite for private UK biotech companiessoared in 2018, with more than double the 2017 total raised. For the first time VC funding broke through the £1bn mark, signalling a welcome return to a steady increase in performance over time.
4 of 4
Venture capital raised: rest of Europe, USA and Asia
With global funding from private and venture sources topping £16.5bn, US biotechs continue to attract the lion’s share. Indeed, two thirds of the global take went to US biotechs. The San Francisco bay area regained pole position as the leading fundraising cluster,securing just over £3.6bn, followed closely by Massachusetts, at just under £3.5bn. China secured the third-place spot at £2.03bn. Combined, European companies raised £2.6bn, with UK firms attracting just under 40% of the total.